awmsg logo



sorafenib (Nexavar®)


Reference No. 284

Publication date:
12/04/2016


Appraisal information

sorafenib (Nexavar®) 200 mg film-coated tablet


Company: Bayer Healthcare Pharmaceuticals
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/02/2016
AWMSG meeting date: 23/03/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0616
Ministerial ratification: 05/04/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sorafenib (Nexavar®) is recommended for restricted use within NHS Wales in the following circumstances for the treatment of hepatocellular carcinoma: • patients with advanced hepatocellular carcinoma for whom surgical or loco-regional therapies have failed or were not suitable. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Sorafenib (Nexavar®) is not recommended for use within NHS Wales outside of these circumstances.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download